

## References

1. Klimov AN, Nikulcheva NG. Saint-Petersburg, 1999. 512 p. (In Russ)
2. Titov VN. *Biohimii – Biochemisrty* 2000;4:3–10. (In Russ)
3. Anderson TJ. Nitric oxide, atherosclerosis and the clinical relevance of endothelial dysfunction. *Heart Fail Rev* 2003;8:71–86.
4. Blake GJ, Otvos JD, Rifai N, Ridker PJ. Low-density lipoprotein particle cardiovascular disease in women. *Circulation* 2002;106:1930–7.
5. Bos MJ, Schipper CM, Koudstaal PJ, Witteman JC, Hofman A, Breteler MM. High serum C-reactive protein level is not an independent predictor for stroke: the Rotterdam Study. *Circulation* 2006;114:1591–8.
6. Celermajer DS, Sorensen KE, Gooch VM. Non-invasive detection of endothelial dysfunction in children and adults at risk of atherosclerosis. *Lancet* 1992;340:1111–5.
7. Chartrain NA, Geller DA, Koty PP, Sitrin NF, Nussler AK, Hoffman EP, Billiar TR, Hutchinson NI, Mudgett JS. Molecular cloning, structure, and chromosomal localization of the human inducible nitric oxide synthase gene. *J Biol Chem* 1994;269:6765–72.
8. Chartrain NA, Geller DA, Koty PP, Sitrin NF, Nussler AK, Hoffman EP, Billiar TR, Hutchinson NI, Mudgett JS. Molecular cloning, structure, and chromosomal localization of the human inducible nitric oxide synthase gene. *J Biol Chem* 1994;269:6765–72.
9. Danesh J, Wheeler JG, Hirschfield GM, Eda S, Eiriksdottir G, Rumley A, Lowe GD, Pepys MB, Gudnason V. C-reactive protein and other circulating markers of inflammation in the prediction of coronary heart disease. *New Engl J Med* 2004;350:1387–97.
10. Everettebcd BM, Bansale S, Rifaif N. Interleukin-18 and the risk of 2009;202:282–8.
11. Festa A, D'Agostino R Jr, Howard G, Mykkänen L, Tracy RP, Haffner SM. Chronic subclinical inflammation as part of the insulin resistance syndrome – The Insulin Resistance Atherosclerosis Study (IRAS). *Circulation* 2000;102:42–7.
12. Guzik TJ, West NE, Black E, McDonald D, Ratnatunga C, Pillai R, Channon KM. Vascular superoxide production by NAD(P)H oxidase. *Circulat Res* 2000;86:E85–E90.
13. Hansson GK. Inflammation, atherosclerosis, and coronary artery disease. *New Engl J Med* 2005;352:1685–95.
14. Harrison DG. Cellular and molecular mechanisms of endothelial cell dysfunction. *J Clin Invest* 1997;19:23–7.
15. Koenig W. Atherosclerosis involves more than just lipids: focus on inflammation. *Eur Heart J* 1999;1(Suppl. T):19–26.
16. Lamas S, Marsden PA, Li GK, Tempst P, Michel T. Endothelial nitric oxide synthase: molecular cloning and characterization of a distinct constitutive enzyme isoform. *Proc Natl Acad Sci USA* 1992;89:6348–52.

17. Noll G, Luscher TF. Influence of lipoproteins of endothelial function. *Thromb Res* 1994;74:S45–S54.
18. Ridker PM, Cannon CP, Morrow D, Rifai N, Rose LM, McCabe CH, Pfeffer MA, Braunwald E; Pravastatin or Atorvastatin Evaluation and Infection Therapy-Thrombolysis in Myocardial Infarction 22 (PROVE IT-TIMI 22) Investigators. C-reactive protein levels and outcomes after statin therapy. *New Engl J Med* 2005;352:20–8.
19. Ridker PM, Rifai N, Stampfer MJ, Hennekens CH. Plasma concentration of interleukin-6 and the risk of future myocardial infarction among apparently healthy men. *Circulation* 2000;101:1767–1772.
20. Ridker PM, Wilson PWF, Grundy SM. Should C-reactive protein be added to metabolic syndrome and to assessment to global cardiovascular risk? *Circulation* 2004;109:2818–2825.
21. Ross R, Harker L. Hyperlipidemia and atherosclerosis. *Science* 1976; 193:1094–100.
22. Sumiyoshi K, Mokuno H, Iesaki T, Shimada K, Miyazaki T, Kume A, Kiyonagi T, Kuremoto K, Watanabe Y, Tada N, Daida H. Deletion of the Fc receptors – chain preserves endothelial function affected by hypercholesterolemia in mice fed on a high-fat diet. *Cardiovasc Res* 2008;80:463–70.
23. Willerson JT, Ridker PM. Inflammation as a cardiovascular risk factor. *Circulation* 2004;109:II-2-II-10.
24. Yoshizumi M, Perrella MA, Bumett JC, Lee M-E. Tumor necrosis factor downregulates an endothelial nitric oxide synthase mRNA by shortening its half-life. *Circulat Res* 1993;73:205–9.